About 7 million couples in the US have difficulty getting or staying pregnant. A new biotech is using insights into the biology of male reproductive cells—the sperm that must meet its female equivalent, an egg cell, for fertilization to occur—to develop products meant to make assisted reproductive technologies such as in vitro fertilization (IVF) more effective.
Cambridge, MA-based Ohana Biosciences (named after a Hawaiian term meaning “family,” as Salesforce (NYSE: CRM) fans may know) debuted publicly on Monday. The company is the latest spinout from venture firm Flagship Pioneering, which founded Ohana in 2016 to explore sperm biology and… Read more »
UNDERWRITERS AND PARTNERS
